OFATUMUMAB (Kesimpta ®)

Clinical Indication

For treating relapsing multiple sclerosis


In line with NICE TA699

Implementation date 19th August 2021

Date of classification

July 2021

Review date

July 2021


Medicines which should be prescribed only in a specialist setting usually within a secondary or tertiary care service. NB: Some highly specialised RED medicines e.g. injectable treatments for cancer are not included on the LLR APC website list.